Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros












Base de dados
Intervalo de ano de publicação
1.
J Vet Med Sci ; 86(1): 18-27, 2024 Jan 10.
Artigo em Inglês | MEDLINE | ID: mdl-37952972

RESUMO

Although chemotherapy using CHOP-based protocol induces remission in most cases of canine multicentric high-grade B-cell lymphoma (mhBCL), some cases develop early relapse during the first induction protocol. In this study, we examined the gene expression profiles of canine mhBCL before chemotherapy and investigated their associations with early relapse during the first whole CHOP-based protocol. Twenty-five cases of mhBCL treated with CHOP-based protocol as first induction chemotherapy were included in this study. Sixteen cases completed the first whole CHOP-based protocol without relapse (S-group), and nine developed relapse during the chemotherapy (R-group). RNA-seq was performed on samples from neoplastic lymph nodes. Differentially expressed genes (DEGs) were extracted by the comparison of gene expression profiles between S- and R-groups, and the differences in the expression levels of these genes were validated by RT-qPCR. Extracted 179 DEGs included the genes related to chemokine CC motif ligand, T-cell receptor signaling pathway, and PD-L1 expression and PD-1 checkpoint pathway. We focused on chemokine CC motif ligand, and CCL4 was confirmed to be significantly downregulated in the R-group (P=0.039). We also focused on the genes related to T-cell signaling pathway, and CD3E (P=0.039), ITK (P=0.023), and LAT (P=0.023) genes were confirmed to be significantly upregulated in the R-group. The current results suggest that both changes in tumor cells and the interactions between tumor cells and immune cells are associated with the efficacy of the chemotherapy for first remission induction.


Assuntos
Doenças do Cão , Linfoma de Células B , Animais , Cães , Transcriptoma , Ligantes , Recidiva Local de Neoplasia/veterinária , Linfoma de Células B/tratamento farmacológico , Linfoma de Células B/genética , Linfoma de Células B/veterinária , Vincristina/uso terapêutico , Doxorrubicina/uso terapêutico , Indução de Remissão , Doença Crônica , Quimiocinas/uso terapêutico , Doenças do Cão/tratamento farmacológico , Doenças do Cão/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...